Investors: Forbion
Memento Medicines closed $93M Series A co-led by Forbion to develop a bispecific antibody targeting Tie2 agonism and VEGF inhibition for wet AMD and diabetic macular edema.
View article →Investors: Forbion, RA Capital Management, Avego BioScience Capital, Sanofi Ventures, Samsara BioCapital
Memento Medicines closed a $93M Series A to develop MMT-205, a bispecific antibody targeting Tie2 activation and VEGF inhibition for nAMD and DME, with potential milestone payments up to $1.08B from licensed partners MabTics and Curacle.
View article →Memento Medicines launches with $93M to fix retinal disease vasculature
Memento Medicines raised $93M Series A to advance a bispecific antibody that simultaneously activates Tie2 and blocks VEGF, a dual mechanism no approved retinal therapy currently uses.
Memento launches $93M bispecific bet against retinal disease standard
Memento Medicines raised $93M to develop MMT-205, a dual-mechanism antibody challenging anti-VEGF monotherapy dominance in nAMD and DME markets worth billions annually.